AstraZeneca and Merck said Japanese regulators had approved their ovarian cancer drug as a front-line therapy following positive clinical trial results.
AstraZeneca said its lung disease drug had been approved in Japan to be used in a pressurised metered-dose inhaler to relieve symptoms in patients with...